PHAXIAM Therapeutics (PHXM) News Today $3.10 0.00 (0.00%) As of 04/2/2025 Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Phaxiam Therapeutics S.A.March 28, 2025 | wsj.comPHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership ProcedureMarch 15, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results PublicationMarch 6, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Press Release Regarding Suspension of TradingMarch 6, 2025 | finance.yahoo.comPHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage TherapyJanuary 31, 2025 | businesswire.comPHAXIAM Therapeutics Announces Its Financial Calendar for 2025January 13, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in EuropeJanuary 7, 2025 | finance.yahoo.comPHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical StudyDecember 31, 2024 | finance.yahoo.comPHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy areaNovember 27, 2024 | globenewswire.comPHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"November 18, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | finanznachrichten.dePHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | globenewswire.comPHAXIAM Therapeutics S.A. (PHXM.PA)November 6, 2024 | finance.yahoo.comPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.November 4, 2024 | globenewswire.comPHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 studyOctober 9, 2024 | finance.yahoo.comPhaxiam Therapeutics S.A.: PHAXIAM Provides Business and Financial Update For the First Half of 2024September 26, 2024 | finanznachrichten.dePHAXIAM Provides Business and Financial Update For the First Half of 2024September 25, 2024 | globenewswire.comResults of the Combined General Meeting of 28 June 2024June 28, 2024 | globenewswire.comPHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024June 7, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM provides Business and Financial Update for the First Quarter of 2024May 15, 2024 | finanznachrichten.dePHAXIAM provides Business and Financial Update for the First Quarter of 2024May 15, 2024 | globenewswire.comPhaxiam enrols first patient in endocarditis infection studyApril 15, 2024 | msn.comPHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureusApril 15, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)April 5, 2024 | finanznachrichten.dePHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)April 5, 2024 | globenewswire.comONCT Oncternal Therapeutics, Inc.March 23, 2024 | seekingalpha.comPHAXIAM Announces 2023 Full-Year Results and Provides Business UpdateMarch 20, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketMarch 11, 2024 | finanznachrichten.dePhaxiam Therapeutics Says Delisting Of ADSs From Nasdaq EffectiveMarch 11, 2024 | markets.businessinsider.comPHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketMarch 11, 2024 | globenewswire.comMonthly information related to total number of voting rights and shares composing the share capital - February 29, 2024March 5, 2024 | finance.yahoo.comTrading was temporarily halted for "PHXM" at 09:02 AM with a stated reason of "LULD pause."February 21, 2024 | marketbeat.comTrading was temporarily halted for "PHXM" at 04:02 PM with a stated reason of "News pending."February 20, 2024 | marketbeat.comPHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketFebruary 20, 2024 | globenewswire.comMonthly information related to total number of voting rights and shares composing the share capital - January 31, 2024February 7, 2024 | finance.yahoo.comPhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024January 19, 2024 | finanznachrichten.dePHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024January 18, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - December 31, 2023January 3, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - November 30, 2023December 6, 2023 | finance.yahoo.comPhaxiam Therapeutics Share Price (PHXM.PA)November 28, 2023 | lse.co.ukPhaxiam Therapeutics S.A.: PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023November 15, 2023 | finanznachrichten.dePHAXIAM Therapeutics SA ADR PHXMNovember 14, 2023 | morningstar.comPHAXIAM Provides Business and Financial Update for the Third Quarter of 2023November 14, 2023 | finance.yahoo.comTrading was temporarily halted for "PHXM" at 10:11 AM with a stated reason of "LULD pause."November 14, 2023 | marketbeat.comPHAXIAM Therapeutics SA ADRNovember 11, 2023 | morningstar.comMonthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023November 7, 2023 | finance.yahoo.comPhaxiam Therapeutics SA DRC (PHXM)October 29, 2023 | investing.comPHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureusOctober 24, 2023 | finance.yahoo.comPhaxiam Therapeutics S.A.: TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a "Buy" recommendationOctober 23, 2023 | finanznachrichten.deTP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendationOctober 23, 2023 | finance.yahoo.com Remove Ads Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address PHXM Media Mentions By Week PHXM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHXM News Sentiment▼0.000.62▲Average Medical News Sentiment PHXM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHXM Articles This Week▼00▲PHXM Articles Average Week Remove Ads Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OKYO Pharma News Today Iterum Therapeutics News Today Dyadic International News Today Aadi Bioscience News Today Werewolf Therapeutics News Today iBio News Today Medicus Pharma News Today Century Therapeutics News Today AlloVir News Today Verrica Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHXM) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHXM Stock Free PHXM Stock Alerts